News from venaxis, inc

Jul 16, 2014, 09:15 ET

Venaxis Reports on Recent FDA Submission Activities

CASTLE ROCK, Colo., July 16, 2014 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA...

Jul 01, 2014, 16:10 ET

Venaxis to Present at ICV Company Outreach Summit

Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™...

May 21, 2014, 16:15 ET

Venaxis to Participate in 11th Annual Craig-Hallum Institutional Investor Conference

Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™...

Apr 08, 2014, 16:01 ET

Venaxis, Inc. Closes Public Offering of Common Shares

 Venaxis, Inc. (NASDAQ:APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked...

Apr 03, 2014, 09:00 ET

Venaxis, Inc. Prices $20.0 Million Public Offering of Common Shares

 Venaxis, Inc. (NASDAQ: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked...

Apr 02, 2014, 16:01 ET

Venaxis, Inc. Announces Proposed Public Offering of Common Shares

Venaxis, Inc. (NASDAQ: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™...

Mar 31, 2014, 07:30 ET

Venaxis Files for FDA Clearance of APPY1 Test

CASTLE ROCK, Colo., March 31, 2014 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA...

Mar 13, 2014, 07:00 ET

Venaxis Announces Positive Top-Line Results from Pivotal Study of APPY1 Test

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked...

Mar 12, 2014, 17:15 ET

Venaxis to Discuss Top-Line Results from Pivotal Study of APPY1 Test

Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™...

Jan 24, 2014, 07:33 ET

Venaxis Completes Patient Enrollment in Pivotal Clinical Trial of APPY1™ Test

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1...

Jan 09, 2014, 09:09 ET

Venaxis to Present at Biotech Showcase™ 2014

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™...

Nov 21, 2013, 16:05 ET

Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference

CASTLE ROCK, Colo., Nov. 21, 2013 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance...

Nov 07, 2013, 16:05 ET

Venaxis to Present at Canaccord Genuity Medical Technology & Diagnostics Forum

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked...

Nov 07, 2013, 07:30 ET

Venaxis Nears Completion of Pivotal Clinical Trial of APPY1™ Test

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE...

Oct 31, 2013, 16:10 ET

Venaxis to Provide Third Quarter 2013 Business Update

Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™...

Sep 26, 2013, 07:30 ET

Venaxis' APPY1™ Test Passes Final Futility Analysis in Pivotal Clinical Study

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1...

Sep 05, 2013, 07:35 ET

Venaxis to Present at Three Upcoming Investor Conferences

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test,...

Aug 08, 2013, 10:59 ET

Venaxis to Present at Canaccord Genuity 33rd Annual Growth Conference

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™...

Jul 15, 2013, 07:30 ET

Venaxis' APPY1 Test Passes Futility Analysis in Pivotal Clinical Study

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test,...

Jun 13, 2013, 07:30 ET

JAMA Pediatrics Study Highlights Cancer Risk Associated with CT Scans

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
ReportBuyer
Investor-Edge